Search in:

Drug Design, Development and Therapy Volume 10, 2016 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations

Jan Dörr1 Multiple Sclerosis Center, Neurology Department, Klinik Hennigsdorf, Hennigsdorf;2 NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, GermanyCorrespondence[email protected]

Karl Baum1 Multiple Sclerosis Center, Neurology Department, Klinik Hennigsdorf, Hennigsdorf

Pages 3379-3386 | Published online: 18 Oct 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (9)

J.E. Meca-Lallana, M. Fernández-Prada, E. García Vázquez, S. Moreno Guillén, S. Otero Romero, M. Rus Hidalgo, L.M. Villar Guimerans, S. Eichau Madueño, Ó. Fernández Fernández, G. Izquierdo Ayuso, J.C. Álvarez Cermeño, C. Arnal García, R. Arroyo González, L. Brieva Ruiz, C. Calles Hernández, A. García Merino, M. González Plata, M.Á. Hernández Pérez, E. Moral Torres, J. Olascoaga Urtaza, P. Oliva-Nacarino, C. Oreja-Guevara, R. Ortiz Castillo, A. Oterino, J.M. Prieto González, L. Ramió-Torrentá, A. Rodríguez-Antigüedad, A. Saiz, M. Tintoré & X. Montalbán Gairin. (2022) Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurología (English Edition) 37:8, pages 615-630.
Crossref

J.E. Meca-Lallana, M. Fernández-Prada, E. García Vázquez, S. Moreno Guillén, S. Otero Romero, M. Rus Hidalgo, L.M. Villar Guimerans, S. Eichau Madueño, Ó. Fernández Fernández, G. Izquierdo Ayuso, J.C. Álvarez Cermeño, C. Arnal García, R. Arroyo González, L. Brieva Ruiz, C. Calles Hernández, A. García Merino, M. González Platas, M.Á. Hernández Pérez, E. Moral Torres, J. Olascoaga Urtaza, P. Oliva-Nacarino, C. Oreja-Guevara, R. Ortiz Castillo, A. Oterino, J.M. Prieto González, L. Ramió-Torrentá, A. Rodríguez-Antigüedad, A. Saiz, M. Tintoré & X. Montalbán Gairin. (2022) Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España. Neurología 37:8, pages 615-630.
Crossref

M.V. Zhuravleva, M.V. Davydovskaya, E.V. Luchinina, T.V. Shelekhova, D.O. Kurguzova & S.Yu. Serebrova. (2020) Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:8, pages 148.
Crossref

Heinz WiendlMatthew CarraroGiancarlo ComiGuillermo IzquierdoHo Jin KimBasil SharrackCarlo TornatoreNadia DaizadehLuke ChungAlan K. JacobsRichard J. HoganLinda V. WychowskiBart Van Wijmeersch. (2020) Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurology Neuroimmunology & Neuroinflammation 7:1.
Crossref

Stuart Cook, Thomas Leist, Giancarlo Comi, Xavier Montalban, Gavin Giovannoni, Axel Nolting, Christine Hicking, Andrew Galazka & Elke Sylvester. (2019) Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Multiple Sclerosis and Related Disorders 29, pages 157-167.
Crossref

Serena Ruggieri, Simona Pontecorvo, Carla Tortorella & Claudio Gasperini. (2018) Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Multiple Sclerosis and Demyelinating Disorders 3:1.
Crossref

Konstantin Huhn, Antonios Bayas, Sebastian Doerck, Benedikt Frank, Kathrin Gerbershagen, Kerstin Hellwig, Boris Kallmann, Christoph Kleinschnitz, Ingo Kleiter, De-Hyung Lee, Volker Limmroth, Mathias Mäurer, Sven Meuth, Peter Rieckmann, Tobias Ruck, Ralf Gold & Ralf A. Linker. (2018) Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Journal of Neurology 265:7, pages 1521-1527.
Crossref

Marieke van der Zwan, Carla C. Baan, Teun van Gelder & Dennis A. Hesselink. (2017) Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. Clinical Pharmacokinetics 57:2, pages 191-207.
Crossref

JASNA JANCIC, BLAŽO NIKOLIC, NIKOLA IVANCEVIC, BORIS HENCIC & JANKO SAMARDŽIC. 2017. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis 39 52 .

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations

Articles from other publishers (9)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations

Citations (9)

Articles from other publishers (9)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date